IKT - Inhibikase Therapeutics GAAP EPS of -$0.18 revenue of $0.05M May, 16 2022 05:07 PM Inhibikase Therapeutics Inc. Inhibikase Therapeutics press release (NASDAQ:IKT): Q1 GAAP EPS of -$0.18. Revenue of $0.05M (-96.5% Y/Y). For further details see: Inhibikase Therapeutics GAAP EPS of -$0.18, revenue of $0.05M